Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10results about How to "Binding block" patented technology

Method for purifying anti-IL-11 monoclonal antibody

ActiveCN119080928A
The invention relates to the field of biological medicines, and particularly provides a purification method of an anti-IL-11 monoclonal antibody, which comprises the following steps: affinity chromatography: preliminarily purifying and concentrating a target protein containing the anti-IL-11 monoclonal antibody, and carrying out virus inactivation on a protein product in an acid solution to obtain a protein sample; anion exchange chromatography: carrying out secondary purification on the protein sample, and collecting flow-through liquid; and cation exchange chromatography: carrying out refined purification on the flow-through liquid to obtain a protein solution of the anti-IL-11 monoclonal antibody. A proper purification process is provided for the anti-IL-11 monoclonal antibody, the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved, flow-through liquid collected by anion exchange chromatography directly enters cation exchange chromatography without treatment, sample treatment or solution replacement is not needed in the process, the purification time is saved, and the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved. Impurities are prevented from being introduced in the purification process, the purity of purified protein is improved, and high practicability is achieved.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

Antibody binding to IL-11, antigen binding fragment and application thereof

The present invention relates to the field of biological medicine, and particularly provides an IL-11 binding antibody or an antigen binding fragment thereof, the antibody comprises three heavy chain complementarity determining regions represented by HCDR1, HCDR2 and HCDR3 respectively and three light chain complementarity determining regions represented by LCDR1, LCDR2 and LCDR3 respectively, and the antibody or the antigen binding fragment thereof is selected from A-I, A-II, A-III or A-IV. The antibody or the antigen binding fragment thereof provided by the invention has relatively high binding capacity with the IL-11 antigen, and can block the binding of the IL-11 antigen and a receptor thereof, so that the fibrosis promoting effect of the IL-11 is effectively inhibited, the generation or proliferation of fibrocytes is inhibited or prevented, and the anti-fibrosis effect of the IL-11 is improved. The compound can be effectively used for treating or preventing human fibrosis diseases, inflammations, cancers or autoimmune diseases.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

Medicinal preparation of anti-IL-11 monoclonal antibody

The invention relates to the field of biological medicine, and particularly provides a pharmaceutical preparation of an anti-IL-11 monoclonal antibody, the pharmaceutical preparation comprises the anti-IL-11 monoclonal antibody, a buffer salt, a protein protective agent and a surfactant, and the anti-IL-11 monoclonal antibody comprises three heavy chain complementary determining regions respectively represented by HCDR1, HCDR2 and HCDR3 and three light chain complementary determining regions respectively represented by LCDR1, LCDR2 and LCDR3. According to the present invention, the buffer salt, the protein protective agent and the surfactant are synergistically matched to provide the suitable storage condition for the high-concentration anti-IL-11 monoclonal antibody, such that the particle performance of the pharmaceutical preparation is significantly changed, and the aggregate generation rate of the anti-IL-11 monoclonal antibody during the production, transportation and use process is reduced; the stability of physicochemical properties of the anti-IL-11 monoclonal antibody is improved, the potential safety risk is reduced, and the stability of a medicinal preparation is ensured.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

A polypeptide specifically binding to coronavirus s protein, encoding gene and application thereof

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.
Owner:PRECEDO PHARMA CO LTD

Phalaenopsis fresh cut flower preservation solution and application thereof

The invention discloses a butterfly orchid fresh cut flower fresh-keeping solution, relates to the field of fresh-keeping after fresh cut flowers are picked, and mainly discloses an optimal combination of the fresh-keeping solution which contains 2g / L of sucrose, 250mg / L of citric acid, 0.5 g / L of 20% sodium dichloroisocyanurate, 5mg / m < 3 > of 1-methylcyclopropene and the balance of water. And the flower vase cutting period of the phalaenopsis amabilis is prolonged.
Owner:FUJIAN AGRI & FORESTRY UNIV

An injection preparation of anti-lilrb4 monoclonal antibody

The present application relates to the field of biological medicine, and specifically provides an anti-LILRB4 monoclonal antibody injection preparation, which comprises an anti-LILRB4 monoclonal antibody, a buffer salt, a protein protective agent, and a surfactant, wherein the pH of the injection preparation is 5.5-6.5. The injection preparation provided by the present application provides a good storage environment for the anti-LILRB4 monoclonal antibody through the synergistic interaction of different contents of the buffer salt, the protein protective agent, and the surfactant, and guarantees the biological activity of the anti-LILRB4 monoclonal antibody. The anti-LILRB4 monoclonal antibody can effectively inhibit the combination of the LILRB4 antigen and its ligand complex, thereby blocking the interaction with the ligand ApoE complex, preventing the activation of the downstream NF-kappa B signal pathway and the release of ARG1, preventing the inhibition of T cell proliferation and the promotion of tissue infiltration, and can be used for treating cancer.
Owner:BEIJING DONGFANG BIOTECH CO LTD

Nanobodies targeting human lllrb2 and uses thereof

Disclosed are an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector comprising the nucleic acid, a pharmaceutical composition comprising the nanobody, and a use for preparing a medicament.
Owner:BEIJING KOHNOOR SCI & TECH CO LTD

Anti-pd-1 / vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof

ActiveIL281116Bbinding blockRelief of immunosuppression
An anti-VEGFA and anti-PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof belong to the field of tumor therapy and molecular immunology. Specifically, the anti-VEGFA and anti-PD-1 bifunctional antibody comprises: a first protein functional region targeting VEGFA, and a second protein functional region targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 on an organism, and inhibit tumor-induced angiogenesis, and thus has good application prospects.
Owner:AKESO BIOPHARMA INC

Antibodies or antigen-binding fragments thereof against tl1a and methods of making and using the same

This invention discloses an anti-TL1A antibody or its antigen-binding fragment, its preparation method, and its applications, relating to the field of antibody technology. The antibody or its antigen-binding fragment of this invention comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises three complementary determinants HCDR1, HCDR2, and HCDR3 as shown in positions 31-35, 50-66, and 99-104 of SEQ ID NO:1, respectively; the light chain variable region comprises three complementary determinants LCDR1, LCDR2, and LCDR3 as shown in positions 24-35, 51-57, and 90-98 of SEQ ID NO:2, respectively. This antibody or its antigen-binding fragment exhibits excellent affinity and binding properties to the TL1A protein and can be used for the prevention and / or treatment of TL1A-mediated diseases.
Owner:CHINA RESOURCES BIOPHARMACEUTICAL CO LTD

Nanobodies targeting human lllrb2 and uses thereof

This invention discloses an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector containing the nucleic acid, a pharmaceutical composition containing the nanobody, and its use in preparing a pharmaceutical product.
Owner:BEIJING KOHNOOR SCI & TECH CO LTD